Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma
Authors:
- Xue-Liang FuXFXue-Liang Fu
- Jian-Yu YangJYJian-Yu Yang
- De-Jun LiuDLDe-Jun Liu
- Jiao LiJLJiao Li
- Jun-Feng ZhangJZJun-Feng Zhang
- Yan-Miao HuoYHYan-Miao Huo
- Min-Wei YangMYMin-Wei Yang
- Rong HuaRHRong Hua
- Yong-Wei SunYSYong-Wei Sun
Open Access
- 1 April 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (15) , e3009
Abstract
We have conducted a meta-analysis and systematic review to determine the overall survival, mortality rate, and complete resection rate of neo-adjuvant chemoradiotherapy (CRT) compared with pancreaticoduodenectomy alone in patients with pancreatic adenocarcinoma. Whether neo-adjuvant CRT is beneficial in the treatment of resectable pancreatic cancer or not, it is still a controversial issue. Medline and Cochrane were searched with relevant terms. Eight studies with a total of 833 participants were selected. The meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The analysis revealed neo-adjuvant group may have a benefit in the overall survival, as compared with the resection group, although it did not reach statistical significance (pooled hazard ratio = 0.87, 95% confidence interval [CI] = 0.75-1.00, P = 0.051). We found no difference in the in-hospital mortality rate (pooled odds ratio [OR] = 1.27, 95% CI = 0.35-4.58, P = 0.710). The complete resection rate was significantly higher in the neo-adjuvant group than in the resection group (pooled OR = 2.39, 95% CI = 1.21-4.74, P = 0.012). This meta-analysis found that there was no significant difference in the overall survival between patients treated with neo-adjuvant CRT or pancreaticduodenectomy.Keywords
This publication has 23 references indexed in Scilit:
- Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?Journal of Surgical Oncology, 2012
- A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic CancerJournal of Gastrointestinal Surgery, 2011
- Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective StudiesAnnals of Surgical Oncology, 2011
- Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trialsSurgery, 2011
- Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trialsBMJ, 2011
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection PercentagesPLOS Medicine, 2010
- A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic CancerAnnals of Surgical Oncology, 2009
- Surgical Results After Preoperative Chemoradiation Therapy for Patients With Pancreatic CancerPancreas, 2009
- Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategyEuropean Journal of Surgical Oncology, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003